Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-01-07
2010-10-12
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S227100, C536S023720, C536S023400, C435S320100
Reexamination Certificate
active
07811576
ABSTRACT:
The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.
REFERENCES:
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4683136 (1987-07-01), Milich et al.
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5726011 (1998-03-01), Milich et al.
patent: 5990085 (1999-11-01), Ireland et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6406705 (2002-06-01), Davis et al.
patent: 6518014 (2003-02-01), Seifer et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 6887464 (2005-05-01), Coleman et al.
patent: 2003/0054337 (2003-03-01), Birkett
patent: 2003/0099668 (2003-05-01), Bachmann et al.
patent: 2003/0138769 (2003-07-01), Birkett
patent: 2003/0175296 (2003-09-01), Brown
patent: 2003/0175863 (2003-09-01), Birkett
patent: 2003/0185854 (2003-10-01), Birkett et al.
patent: 2003/0185858 (2003-10-01), Birkett
patent: 2003/0198645 (2003-10-01), Page
patent: 2003/0202982 (2003-10-01), Birkett
patent: 2004/0054139 (2004-03-01), Page et al.
patent: 2004/0146524 (2004-07-01), Lyons et al.
patent: 2004/0152876 (2004-08-01), Birkett
patent: 2004/0156864 (2004-08-01), Birkett
patent: 2004/0219164 (2004-11-01), Coleman et al.
patent: 7252300 (1995-10-01), None
patent: WO 95/27083 (1995-10-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 00/46365 (2000-08-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 02/013765 (2002-12-01), None
Pumpens et al (Intervirology 38:63-74, 1995).
Billaud et al (Journal of Virology 79:13641-13655, 2005).
Billaud et al (Journal of Virology 79:13656-13666, 2005).
Schodel et al. (1994) “Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes,” J Exp Med. 180:1037-1046.
Schodel et al. (1997) “Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice AgainstPlasmodium yoeliiChallenge,” Behring Inst Mitt. 114-119.
Milich et al. (1997) “Role of B cells in antigen presentation of the hepatitis B core,” Proc Natl Acad Sci USA 94:14648-14653.
Kratz et al. (1999) “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids,” Proc Natl Acad Sci USA 96:1915-1920.
Chen et al. (2000) “Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection,” J. Virol. 74:7587-7599.
Lazdina et al. (2001) “Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells,” J Virol. 75:6367-6374.
Cao et al. (2001) “Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model,” J Virol. 75:6359-6366.
Anttila et al. (1998) “Avidity of IgG forStreptococcus pneumoniaeType 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines,” J Infect Dis. 177:1614-1621.
Arad et al. (2000) “Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation,” Nat Med. 6:414-421.
Visvanathan et al. (2001) “Inhibition of Bacterial Superantigens by Peptides and Antibodies,” Infect Immunol. 69:875-884.
DeVelasco et al. (1994) “Adjuvant Quil A improves protection in mice and enhaces opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines,” Vaccine 12:1419-1422.
Koletzki et al. (1997) “Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments,” J Gen Virol. 78:2049-2053.
Smiley and Minion (1993) “Enhanced readthrough of opal (UGA) stop codons and production ofMycoplasma pneumoniaeP1 epitopes inEscherichia coli,” Gene 134:33-40.
GenBank Accession No. NM 009778 printed Apr. 2003.
Dempsey et al. (1996) “C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity,” Science 271:348-350.
Tedder et al. (1994) “The CD19/CD21 signal transduction complex of B lymphocytes,” Immunol Today 15:437-442.
GenBank Accession No. X65453 printed Apr. 2001.
Morris et al. (1999) “Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD4OL (CD154),” J. Biol. Chem. 274:418-423.
Mackay and Browning (2002) “Baff: A Fundamental Survival Factor for B Cells,” Nature Reviews Immunology 2:465-475.
GenBank Accession No. NM 008479 printed Apr. 2003.
El mir and Triebel (2000) “A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens,” J. Immunol 164:5583-5589.
Krieg et al. (1995) “CpG motifs in bacterial DNA trigger direct B-cell activation,” Nature 374:546-549.
Davis et al. (1998) “CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen,” J. Immunol. 160:870-876.
Fouet et al. (1999) “Bacillus anthracissurface: capsule and S-layer,” J Appl Microbiol. 87:251-255.
Paoletti et al. (2002) “Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen,” Vaccine 20:370-376.
Wang et al. (2003) “Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling,” Vaccine 21:1112-1117.
Bittle et al. (1982) “Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence,” Nature 298:30-33.
Van Lierop et al. (1992) “Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination and immunization with these peptides in cattle,” Immunol. 75:406-413.
Wong et al. (2000) “Plasmids Encoding Foot-and-Mouth Disease Virus VP1 Epitopes Elicited Immune Responses in Mice and Swine and protected Swine against Viral Infection,” Virol. 278:27-35.
Neirynck et al. (1999) “A universal influenza A vaccine based on the extracellular domain of the M2 protein,” Nat Med. 5:1157-1163.
Heinen et al. (2002) “Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleotprotein fusion protein exacerbates disease after challenge with influenza A virus,” J. Gen. Virol. 83:1851-1859.
Pekosz and Lamb (1999) “Cell Surface Expression of Biologically Active Influenza C Virus HEF Glycoprotein Expressed from cDNA,” J Virol. 73:8808-8812.
Hughey et al. (1995) “Effects of Antibody to the Influenza A Virus M2 Protein on M2 Surface Expression and Virus Assembly,” Virol. 212:411-421.
Zebedee and Lamb (1989) “Growth restriction of influenza A virus by M2protein antibody is genetically linked to the M1protein,” Proc Natl Acad Sci USA 86:1061-1065.
Pegram and Slamon (2000) “Biological Rationale for HER2
eu(c-erbB2) as a Target for Monoclonal Antibody Therapy,” Semin Oncol. 27:13-19.
Schenk et al. (1999) “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,” Nature 400:173-177.
Chang (2000) “The pharmacological basis of anti-IgE therapy,” Nat Biotechnol. 18:157-162.
Maini and Taylor (2000) “Anti-Cytokine Therapy for Rheumatoid Arthritis,” Annu Rev Med. 51:207-229.
Chackerian et al. (2001) “Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of prot
Billaud Jean-Noel
Milich David R.
Morrison & Foerster / LLP
Mosher Mary E
Vaccine Research Institute of San Diego
LandOfFree
Rodent hepatitis B virus core proteins as vaccine platforms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rodent hepatitis B virus core proteins as vaccine platforms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rodent hepatitis B virus core proteins as vaccine platforms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155362